LUCENT-3 change from induction baseline in ulcerative colitis symptoms from weeks 52 through 104 (LUCENT-3 weeks 0-52) of continuous mirikizumab treatment in LUCENT-2 week 52 completers for (A) stool frequency (change in stool frequency modified Mayo score subscore from induction baseline), (B) rectal bleeding (change in rectal bleeding modified Mayo score subscore from induction baseline), (C) Abdominal Pain Numeric Rating Scale (NRS), and (D) Urgency NRS, mixed models for repeated measures. The modified intention-to-treat population was used with mixed models for repeated measures to estimate the mean change from baseline. The Abdominal Pain NRS measures change in abdominal pain score from induction baseline. The Urgency NRS measures change in bowel Urgency NRS score from induction baseline. LSM = least-squares mean.